Certara Appoints Jon Resnick as Chief Executive Officer
In a significant leadership transition, Certara, Inc. has announced the appointment of Jon Resnick as its new Chief Executive Officer, effective January 1, 2026. Resnick's impressive background in health sciences and business operations positions him uniquely to lead the company into its next growth phase.
Lead Through Experience
Resnick comes to Certara with over 20 years of accumulated experience at IQVIA, a vital player in the life sciences sector that leverages data and analytics to accelerate the development of therapies. He has most recently held the role of President for the U.S. and Canada regions, where he honed his skills in managing commercial operations.
Before his presidency, Resnick contributed significantly to IQVIA’s Real World Solutions business during its critical merger between IMS Health and Quintiles. His previous stints at IMS Health involved roles that directly influenced the company’s US and EMEA consulting strategies and services.
Vision for Future Innovation
James E. Cashman III, Chairman of the Board of Directors, expressed optimism about Resnick’s leadership. "We are excited to welcome Jon to Certara. His proven track record of innovation in healthcare, as well as his ability to build strong collaborative teams, will be invaluable as we look to leverage model-informed drug development to enhance patient care," Cashman stated.
Commitment to Client Success
Resnick shares this excitement, emphasizing his dedication to Certara's mission. “Joining Certara represents a unique opportunity to be part of a company that is globally recognized for its advancements in drug discovery and development. The capabilities we possess in AI and biosimulation technology put us in a prime position to help clients navigate their challenges effectively,” said Resnick.
Leadership Transition and Legacy
As Resnick steps into his role, William F. Feehery will transition to an advisory position, offering his insights for a smooth transition. Feehery's tenure has been marked by successful milestones, including Certara’s IPO and enhanced investments in software development.
"I am incredibly proud of what we have accomplished at Certara. We have made strides in biosimulation adoption and have empowered our clients to advance their medicines more swiftly and confidently,” said Feehery, highlighting a strong sense of commitment to the company’s future.
Certara’s Upcoming Ventures
In conjunction with this transition, Certara has reaffirmed its financial outlook for 2025, echoing prior announcements made earlier. The company anticipates a robust future, built on the foundation laid by previous leadership while leveraging new strategies introduced by Resnick.
About Certara
Certara stands at the forefront of drug development, utilizing proprietary biosimulation software and data-driven technologies to enhance and transform the traditional processes of drug discovery. With a clientele that spans over 2,400 biopharmaceutical organizations and regulatory bodies across 70 nations, Certara's impact is truly global.
Looking Ahead with Certara
As the life sciences industry continues to evolve, Certara remains committed to empowering its partners with the tools and insights essential for navigating the complex landscape of drug development. With Jon Resnick at the helm, the path forward looks promising and full of possibility.
Frequently Asked Questions
Who is Jon Resnick?
Jon Resnick is the newly appointed CEO of Certara, bringing over 20 years of experience in the life sciences industry.
What did Resnick do before joining Certara?
Prior to Certara, Resnick served as President of IQVIA's U.S. and Canada operations, focusing on business strategy and commercial growth.
What is Certara's mission?
Certara aims to improve drug discovery through innovative biosimulation technologies and software, enhancing the overall development process for pharmaceuticals.
Who will Jon Resnick succeed at Certara?
Jon Resnick will succeed William F. Feehery, who served as CEO and will assist during the transition period.
How does Certara support its clients?
Certara utilizes its expertise to provide biopharmaceutical companies with the necessary tools to minimize risks and accelerate drug development timelines.
